A Phase I, Two-part Study to Determine the Recommended Dose and Evaluate the Safety and Tolerability of a Novel Oral Arsenic Trioxide Formulation (ORH-2014) in Subjects With Advanced Hematological Disorders
Clinical trial NCT03048344 · COMPLETED
Trial details
- NCT number
- NCT03048344
- Sponsor
- Orsenix LLC
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2016-12-02
- Primary completion
- 2019-02-28
- Enrollment
- 12
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.